Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Epinastine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 13/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 5/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 4/20 | 1.00 |
| ▸ | HTR1A | P08908 | 3/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 3/20 | 1.00 |
| ▸ | DRD1 | P21728 | 2/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 2/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | SLC22A2 | O15244 | 1/20 | 1.00 |
| ▸ | GABRA1 | P14867 | 1/20 | 1.00 |
| ▸ | GABRA2 | P47869 | 1/20 | 1.00 |
| ▸ | GABRB2 | P47870 | 1/20 | 1.00 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 1.00 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 15/20 | 0.45 |
| ▸ | HTR2C | P28335 | 12/20 | 0.45 |
| ▸ | DRD2 | P14416 | 4/20 | 0.43 |
| ▸ | DRD4 | P21917 | 3/20 | 0.43 |
| ▸ | DRD3 | P35462 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Epinastine SCHEMBL18794 | 1.00 | ADRA1A (1.00) | ADRA1AADRA2AHTR1AOPRM1DRD1 | |
| Epinastine SCHEMBL29945140 | 1.00 | ADRA1A (1.00) | ADRA1AADRA2AHTR1AOPRM1DRD1 | |
| Epinastine SCHEMBL122749 | 0.98 | ADRA1A (0.97) | ADRA1AADRA2AHTR1AOPRM1DRD1 | |
| Epinastine SCHEMBL4292213 | 0.98 | ADRA1A (0.97) | ADRA1AADRA2AHTR1AOPRM1DRD1 | |
| Epinastine SCHEMBL3989748 | 0.98 | ADRA1A (0.97) | ADRA1AADRA2AHTR1AOPRM1DRD1 | |
| Epinastine SCHEMBL30678575 | 0.98 | ADRA1A (0.97) | ADRA1AADRA2AHTR1AOPRM1DRD1 | |
| Epinastine SCHEMBL3989750 | 0.98 | ADRA1A (0.97) | ADRA1AADRA2AHTR1AOPRM1DRD1 | |
| Epinastine SCHEMBL122751 | 0.98 | ADRA1A (0.97) | ADRA1AADRA2AHTR1AOPRM1DRD1 | |
| Epinastine SCHEMBL122750 | 0.97 | ADRA1A (0.94) | ADRA1AADRA2AHTR1AOPRM1DRD1 | |
| Epinastine SCHEMBL16093961 | 0.90 | ADRA1A (0.81) | ADRA1AADRA2AHTR1AOPRM1DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1274 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | SIO2 MEDICAL PRODUCTS LLC (US) | 2026-03-19 | — | — | US | claimed |
| US-20250242092-A1 | SiOx BARRIER FOR PHARMACEUTICAL PACKAGE AND COATING PROCESS | SIO2 MEDICAL PRODUCTS INC (US) | 2025-07-31 | — | — | US | claimed |
| US-12257371-B2 | SiOx barrier for pharmaceutical package and coating process | SIO2 MEDICAL PRODUCTS, LLC (US) | 2025-03-25 | — | — | US | claimed |
| CN-114072132-B | Bionic tissue adhesive hydrogel patch and application thereof | 赛拉尔研究有限公司 | 2024-11-15 | — | — | CN | claimed |
| CN-112368300-B | SPNS2 neutralizing antibodies | 帝人制药株式会社 | 2024-10-01 | — | — | CN | claimed |
| US-20240074944-A1 | PECVD COATED PHARMACEUTICAL PACKAGING | OAKTREE FUND ADMINISTRATION, LLC | 2024-03-07 | — | — | US | claimed |
| CN-117241773-A | Polymer medicine bottle with standard external dimensions and reduced internal volume | SIO2医疗产品有限公司 | 2023-12-15 | — | — | CN | claimed |
| US-20230303305-A1 | METHOD AND PACKAGE FOR REDUCING THE DEGRADATION OF A DRUG AND/OR EXCIPIENT, E.G. POLYSORBATE STABILIZER, IN A PHARMACEUTICAL PRODUCT | OAKTREE FUND ADMINISTRATION, LLC | 2023-09-28 | — | — | US | claimed |
| EP-4247316-A1 | POLYMER VIALS HAVING STANDARD EXTERNAL DIMENSIONS AND REDUCED INTERNAL VOLUME | SiO2 Medical Products, Inc. (US) | 2023-09-27 | — | — | EP | claimed |
| CN-116782865-A | Atomic layer deposition coated pharmaceutical packages, improved syringes and vials, e.g., for lyophilization/cold chain drugs/vaccines | SIO2医药产品公司 | 2023-09-19 | — | — | CN | claimed |
| WO-2004087095-A2 | OSMOTIC CONTROLLED RELEASE DEVICE CONTAINING ZAFIRLUKAST AND AN H1-ANTAGONIST | OSMOTICA COSTA RICA, SOCIEDAD ANONIMA (CR) | 2004-10-14 | — | — | WO | claimed |
| WO-2004087167-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING EPINASTINE FOR THE TREATMENT OF SKIN DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-10-14 | — | — | WO | claimed |
| CN-1518448-A | Antihistamines for treatment of nasal congestion and nasal obstruction | ���鹫˾ | 2004-08-04 | — | — | CN | claimed |
| WO-2004019955-A1 | THE USE OF THE COMBINATION OF CICLESONIDE AND ANTIHISTAMINES FOR THE TREATMENT OF ALLERGIC RHINITIS | ALTANA PHARMA AG (DE) | 2004-03-11 | — | — | WO | claimed |
| WO-2004019917-A1 | DEVICE FOR RELEASE OF A DRUG CONTAINING OSELTAMIVIR AND A H1 ANTAGONIST | OSMOTICA CORP. (VG) | 2004-03-11 | — | — | WO | claimed |
| WO-2004014353-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING COMBINATIONS OF EPINASTINE, PSEUDOEPHEDRINE AND METHYLEPHEDRINE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-02-19 | — | — | WO | claimed |
| WO-2003074055-A1 | PHARMACEUTICAL COMPOSITION OF A PDE4 OR A PDE3/4 INHIBITOR AND A HISTAMINE RECEPTOR ANTAGONIST | ALTANA PHARMA AG (DE) | 2003-09-12 | — | — | WO | claimed |
| CN-1390129-A | Epinadine-containing solution | BOEHRINGER INGELHEIM INT (DE) | 2003-01-08 | — | — | CN | claimed |
| WO-2002020018-A1 | TABLETS CONTAINING EPINASTINE MANUFACTURED BY DIRECT COMPRESSION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2002-03-14 | — | — | WO | claimed |
| CN-1329490-A | Composition and method for treating allergic diseases | SCHERING CORP (US) | 2002-01-02 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | MEN1, MYO1G, IL2 | HRH1 1733/4885ADRA1A 1456/4885ADRA2A 2289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.